PharmPK Discussion - TINIBS nomenclature

• On 4 Nov 2011 at 00:31:28, isra m (isra971.at.yahoo.com) sent the message
  

  
  Dear all,
  I have a question about anticancer drugs of the tinibs group. Can
  anybody help me to know the bases of the nomenclature of this class of
  drugs? Examples of drugs belonging to this class include:
  (Axitinib, Cediranib, Pazopanib, Regorafenib, Semaxanib, Sorafenib,
  Sunitinib, Toceranib, Vandetanib).
  The addition of an article title related to this subject will be highly
  appreciated.
  Best regards
  
  Isra' Admour, M.Sc Pharm Tech.
  isra971.-a-.yahoo.com
  
  

  Back to the Top

• On 4 Nov 2011 at 13:46:55, Eyob Adane (eyobdebebe.-a-.gmail.com) sent the message
  

  
  The following message was posted to: PharmPK
  
  You might want to take a look at JPET 315:971-979, 2005 (Role of
  Tyrosine Kinase Inhibitors in Cancer Therapy)
  
  

  Back to the Top

• On 7 Nov 2011 at 10:10:22, Andreas Lindauer (alindauer-research.at.ferrergrupo.com) sent the message
  

  
  Dear Isra,
  
  Nomenclature of these drugs follows the INN rules of the WHO (see:
  http://www.who.int/medicines/services/inn/StemBook2009.pdf
  and a presentation by Martha Mims I found here:
  http://www.beyondprinting.com/harvard/SouthWest2010/PDF/S13-945-Mims-Nibs-HOU10%20[Compatibility%20Mode].pdf
  
  Although I don't have a reference explaining in detail how the suffixes
  were developed, I think the following makes sense:
  -tinib       = T-yros-I-ne kinase   i-N-h-IB-itors
  -anib      = A-ngiogenesis   i-N-h-IB-itors
  -rafenib = RAF-kinas-E   i-N-h-IB-itors
  
  Best regards, Andreas.
  
  Dr. Andreas Lindauer
  Modeling & Simulation and in vivo ADME
  Dept. of Pharmacokinetics and Metabolism
  R&D Center. Ferrer Internacional S.A.
  Juan de Sada 32, 08028 Barcelona
  

  Back to the Top

• On 26 Nov 2011 at 19:49:53, kaustuv sahoo (kspharm4u.-at-.gmail.com) sent the message
  

  
  Hi Isra'
  
  they are all tyrosine kinase inhibitors, but inhibiting different
  kinases.  I think you can get some idea from the review below.
  
  thanks and regards,
  Kaustuv Sahoo, PhD student,
  OUHSC, college of pharmacy
  
  JPET 315:971-979, 2005
  Perspectives in Pharmacology
  Role of Tyrosine Kinase Inhibitors in Cancer Therapy, Amit Arora and
  Eric M. Scholar
  
  

  Back to the Top

Copyright 1995-2011 David W. A. Bourne (david@boomer.org)